Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453054 | 0.98 | ALDH1A1 (0.50) | ALDH1A1EPHX2ATMNAAAHPGD | |
| SCHEMBL10103543 | 0.98 | ALDH1A1 (0.50) | ALDH1A1EPHX2ATMNAAAHPGD | |
| SCHEMBL8633605 | 0.98 | ALDH1A1 (0.50) | ALDH1A1EPHX2ATMNAAAHPGD | |
| Hydrochloric Acid SCHEMBL28237612 | 0.96 | ALDH1A1 (0.49) | ALDH1A1EPHX2ATMNAAA | |
| SCHEMBL8694308 | 0.96 | EPHX2 (0.49) | ALDH1A1EPHX2ATMNAAAHPGD | |
| SCHEMBL20994218 | 0.94 | EPHX2 (0.51) | ALDH1A1EPHX2NAAATSHR | |
| SCHEMBL18924835 | 0.92 | NAAA (0.50) | ALDH1A1EPHX2NAAATSHR | |
| SCHEMBL18856231 | 0.92 | NAAA (0.50) | ALDH1A1EPHX2NAAATSHR | |
| SCHEMBL28458353 | 0.92 | NAAA (0.50) | ALDH1A1EPHX2NAAATSHR | |
| SCHEMBL2253748 | 0.92 | NAAA (0.50) | ALDH1A1EPHX2NAAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779015-B2 | Pesticide compositions | FUNDACIÓ CENTRE DE REGULACIÓ GENÓMICA (ES) | 2023-10-10 | — | — | US | claimed |
| US-20200359621-A1 | PESTICIDE COMPOSITIONS | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) | 2020-11-19 | — | — | US | claimed |
| EP-3713415-A1 | PESTICIDE COMPOSITIONS | Fundació Centre de Regulació Genòmica (ES) | 2020-09-30 | — | — | EP | claimed |
| WO-2019101890-A1 | PESTICIDE COMPOSITIONS | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) | 2019-05-31 | — | — | WO | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11779015-B2 | Pesticide compositions | FUNDACIÓ CENTRE DE REGULACIÓ GENÓMICA (ES) | 2023-10-10 | — | — | US | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-4751295-A | 7-(2-(5-AMINO-1,2,4-THIADIAZOL-3-YL)-2-OXYIMINOACETAMIDO)-3-(3 -(QUATERNARY AMMONIO)-1-PROPEN-1-YL)-3-CEPHEM-4-CARBOXYLATES | BRISTOL-MYERS COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200359621-A1 | PESTICIDE COMPOSITIONS | ADH1C, DDT, AKR1C3 | ALDH1A1 35/4885EPHX2 255/4885ATM 3722/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | ALDH1A1 785/4885EPHX2 836/4885ATM 3058/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | ALDH1A1 1158/4885EPHX2 720/4885ATM 2400/4885 |
| US-11779015-B2 | Pesticide compositions | ADH1C, DDT, AKR1C3 | ALDH1A1 35/4885EPHX2 255/4885ATM 3722/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | ALDH1A1 162/4885EPHX2 1264/4885ATM 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.